Graph utilizes perturbation modeling from primary patient cell samples and multi-omics data to develop targeted therapies and biomarkers for immune-mediated diseases. The company addresses the lack of effective treatment options for millions of patients due to the complex nature of these diseases.
Funding
$8.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AWARMGNIFounders
Product
Problem
Millions of patients with immune-mediated diseases lack effective treatment options due to the complex and heterogeneous nature of these conditions. Current therapies often provide limited relief or have significant side effects, highlighting the need for more targeted and personalized approaches.
Solution
Graph employs an AI-driven precision medicine approach, leveraging perturbation modeling from primary patient cell samples and multi-omics data to develop targeted therapies and biomarkers for immune-mediated diseases. By analyzing patient-specific cellular responses to various stimuli, Graph identifies key drivers of disease and predicts therapeutic efficacy. This enables the development of personalized treatment strategies that address the underlying mechanisms of disease, leading to improved patient outcomes. The platform aims to transform drug discovery and development for immune-mediated diseases by providing a more rational and efficient approach.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions focused on developing novel therapies for immune-mediated diseases.
Features
- Perturbation modeling of primary patient cell samples to capture individual disease heterogeneity
- Multi-omics data integration (genomics, transcriptomics, proteomics) for comprehensive disease profiling
- AI-driven analysis to identify key disease drivers and predict therapeutic response
- Biomarker discovery for patient stratification and treatment monitoring
- Targeted therapy development based on patient-specific disease mechanisms